Management of cancer-related fatigue (Q36156911)

12 August 2017

1 reference

title

Management of cancer-related fatigue. (English)

1 reference

12 August 2017

Gary R Morrow

1

1 reference

12 August 2017

Abhay R Shelke

2

1 reference

12 August 2017

Joseph A Roscoe

3

1 reference

12 August 2017

Jane T Hickok

4

1 reference

12 August 2017

Karen Mustian

5

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

23

1 reference

12 August 2017

229-239

1 reference

12 August 2017

3

1 reference

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

12 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Fatigue in advanced cancer: a prospective controlled cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

The impact and management of cancer-related fatigue on patients and families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

The biologic basis of fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Off-treatment fatigue in breast cancer survivors: a controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Assessment and epidemiologic issues related to fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Validity of cancer-related fatigue instruments

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Symptom prevalence, characteristics and distress in a cancer population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Interferon-mediated fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Fatigue and its associated factors in ambulatory cancer patients: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

The relationship between fatigue and sleep in cancer patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Fatigue, depression and quality of life in cancer patients: how are they related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Anorexia and cachexia, asthenia, and lethargy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Cachexia-anorexia-asthenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Effects of exercise on cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Correlation between physical performance and fatigue in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

The impact of hemoglobin levels on fatigue and quality of life in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Depression in advanced disease: a systematic review Part 1. Prevalence and case finding

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Predicting major depression in brain tumor patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Identifying patients at risk for, and treatment of major psychiatric complications of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

New agents for the treatment of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Psychostimulants for depression in hospitalized cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

A prospective trial of modafinil as an adjunctive treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

Acute behavioral and physiological effects of modafinil in drug abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

An evaluation of the abuse potential of modafinil using methylphenidate as a reference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055960

21 January 2018

Identifiers

DOI

10.1081/CNV-200055960

1 reference

12 August 2017

1 reference